Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR splice variants in circulating tumor cells as predictors of resistance to abiraterone or enzalutamide in castration-resistant prostate cancer
NL-OMON42793Not yet recruiting
- Sponsor
- University of Antwerp
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of abiraterone and enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by University of Antwerp. Planned start May 2015; status: not yet recruiting.
02
Drugs
abirateroneenzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON42793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42793.